Scarica l'app Stockscreener
0.9268
10.88%
-0.1132
Dopo l'orario di chiusura:
.93
0.0032
+0.35%
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
MSN Money - MSN
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
aTyr Pharma (ATYR) Projected to Post Earnings on Wednesday - MarketBeat
Interstitial Lung Disease Pipeline Grows as 120+ Pharma - openPR.com
What is the growth outlook for aTyr Pharma (ATYR) stock (Range-Bound) 2026-04-20Entry Points - Xã Thanh Hà
aTyr Pharma Inc stock (US53227K1025): Is efzofitimod's Phase 3 data the real test for pulmonary sarc - AD HOC NEWS
aTyr Pharma stock tanks after missing main goal in lung disease study - MSN
aTyr Pharma (ATYR) Stock: This Quarter (Near Highs) 2026-04-20Community Chart Signals - Cổng thông tin điện tử Tỉnh Sơn La
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
aTyr Pharma (ATYR) Stock Commodity Trade (Investors Pile In) 2026-04-18Shared Momentum Picks - Cổng thông tin điện tử tỉnh Lào Cai
aTyr Pharma, Inc. (ATYR) Stock Analysis: Understanding the 417% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
aTyr Pharma (ATYR) Stock: Overpriced? (Touches High) 2026-04-15Social Trading Insights - Cổng thông tin điện tử tỉnh Lào Cai
aTyr Pharma Inc stock (US53227K1025): Is efzofitimod's pulmonary sarcoidosis data strong enough to u - AD HOC NEWS
Gainers Report: Is aTyr Pharma Inc a momentum stock2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Can aTyr Pharma (ATYR) Stock increase dividends | Price at $0.77, Down 3.64%Target Price - Xã Châu Thành
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: aTyr Pharma (ATYR) and Idexx Laboratories (IDXX) - The Globe and Mail
Market Wrap: Is aTyr Pharma Inc in a bullish channelM&A Rumor & Comprehensive Market Scan Insights - baoquankhu1.vn
ATYR Technical Analysis & Stock Price Forecast - Intellectia AI
Downgrade Watch: Is aTyr Pharma Inc backed by strong institutional buying2026 Stock Rankings & Daily Growth Stock Investment Tips - baoquankhu1.vn
Performance Recap: Is aTyr Pharma Inc in a bullish channel2026 Momentum Check & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
aTyr Pharma (NASDAQ: ATYR) seeks approval to double share authorization - Stock Titan
[ARS] aTYR PHARMA INC SEC Filing - stocktitan.net
Vanguard disaggregates holdings; reports 0 shares in aTyr Pharma (ATYR) - Stock Titan
aTyr Pharma, Inc. (ATYR) Investor Outlook: Exploring a Potential 445% Upside in the Biotech Sector - DirectorsTalk Interviews
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of "Hold" by Analysts - MarketBeat
ATyr Pharma Announces Scheduling of FDA Type - Moomoo
HC Wainwright & Co. Downgrades aTyr Pharma (ATYR) - MSN
aTyr Pharma Inc Stock (ISIN: US53227K1025) Faces Uncertainty Amid Delisting Risk and Pipeline Focus - AD HOC NEWS
aTyr Pharma (NASDAQ:ATYR) Upgraded at Wall Street Zen - MarketBeat
Does aTyr Pharma Inc stock benefit from AI growth2026 Analyst Calls & Precise Entry and Exit Recommendations - baoquankhu1.vn
aTyr Pharma (NASDAQ: ATYR) asks shareholders to double authorized shares to 340M - Stock Titan
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting - MarketBeat
ATYR: Efzofitimod shows durable quality of life gains and is reshaping sarcoidosis treatment practices - TradingView
Investigation announced for Long-Term Investors in shares - openPR.com
aTyr Pharma (ATYR) Receives a Buy from Piper Sandler - The Globe and Mail
Atyr to discuss efzofitimod’s future with FDA after Phase 3 sarcoidosis trial - Sarcoidosis News
Q1 Earnings Estimate for aTyr Pharma Issued By HC Wainwright - MarketBeat
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation - The Globe and Mail
Jefferies Maintains Buy on ATYR aTyr Pharma, Inc. March 2026 - Meyka
Jefferies reiterates aTyr Pharma stock rating on regulatory outlook By Investing.com - Investing.com Canada
Jefferies reiterates aTyr Pharma stock rating on regulatory outlook - Investing.com UK
aTyr Pharma 2025 Financials: Q4 Loss Narrows, Annual Revenue SteadyNews and Statistics - IndexBox
Atyr Pharma: Fourth Quarter Earnings Overview - Bitget
aTyr Pharma (NASDAQ:ATYR) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
aTyr (ATYR) Achieves Milestone with Phase 3 Study Results - GuruFocus
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update - The Manila Times
Atyr Pharma: Q4 Earnings Snapshot - marketscreener.com
ATyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update - marketscreener.com
Why Is aTyr Stock Falling Today? - Stocktwits
aTyr Pharma (ATYR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
ATYR Financials: Income Statement, Balance Sheet & Cash Flow | Atyr Pharma Inc - Stock Titan
ATYR PE Ratio & Valuation, Is ATYR Overvalued - Intellectia AI
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of "Hold" by Analysts - marketbeat.com
aTyr Pharma Faces Pivotal Regulatory and Financial Milestones - AD HOC NEWS
1.87%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):